Interim report January-March 2009

Interim report January-March 2009

January-March

•  Group revenues from sales of goods and royalties amounted to 339 (289) MSEK. 

•  Earnings per share amounted to 0.42 (0.10) SEK. 

•  Operating income amounted to 54 (10) MSEK. 

•  Revenues within the Esthetics product area amounted to 269 (233) MSEK and
operating income was 50 (55) MSEK.

•  Net income after tax amounted to 42 (10) MSEK.

Important events after the end of the period

•  On April 22 Q-Med announced that Q-Med AB and Oceana Therapeutics, LCC.,
based in the US, have entered into global agreements regarding commercialization
rights to Deflux® and Solesta™. The agreements also include future products that
utilize Q-Med's proprietary NASHA™ technology within the areas of
gastroenterology and urology. As part of the transaction Oceana Therapeutics is
acquiring Q-Med Scandinavia Inc., which accounts for the majority of the
business for Deflux and Solesta. 
Under the terms of the agreements Oceana will make an initial payment of 60 MUSD
for the shares of Q-Med Scandinavia, Inc. and an additional payment of 15 MUSD
upon the US approval of Solesta. Under the agreements, if certain sales targets
are achieved, Q-Med AB may receive additional milestone payments of up to 45
MUSD. Oceana will also pay a royalty for the licensing rights based on the net
sales of the products. The parties will share the clinical development cost of
Solesta.
The transaction is subject to authority approval and to the closing conditions
between the parties being met.  

Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: + 46 70-974 9025  
Alexander Kotsinas, Vice President and CFO
Tel: +46 73-500 1111

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA™, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane™ for body contouring, Durolane™ for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta™ for the treatment of fecal incontinence. Sales are made through the
company's own subsidiaries or distributors in over 70 countries. Q Med today has
just over 650 coworkers, with close to 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap
segment of NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Tel: 018-474 90 00, Fax:
018-474 90 01
info@q-med.com, www.q-med.com, Corporate identity number 556258-6882

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.